El Granada, CA, United States of America

John William Winslow

This inventor holds 24 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Neurotrophic Factors. Top assignees: Genentech, Inc., Laboratory Corporation of America Holdings, Exelixis, Inc.. Active years: 1998-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John William Winslow. Retrieved from https://idiyas.com/inventor/john-william-winslow

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 3)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 220(Granted Patents)

Location History:

El Grenada, CA (US) (2001 - 2012)
El Granada, CA (US) (1998 - 2023)

Company Filing History:

Laboratory Corporation of America Holdings

Monogram Biosciences, Inc.

patents

6. 1 out of 834,570

Other

patents

Years Active: 1998-2023

Loading Chart...

Areas of Expertise:

Neurotrophic Factors

Cancer Diagnostics

Antibody Production

NGF Variants

AL-1 Factor

Metastasis Prediction

Cognitive Function

Invertebrate VEGF

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11579148 - Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients (2023-02-14),

2. 11401344 - Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients (2022-08-02),

3. 10416162 - Her2 diagnostic methods (2019-09-17),

4. 10273308 - Methods of producing antibodies specific for p95 (2019-04-30),

5. 9081019 - Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 (2015-07-14),

6. 8470542 - Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 (2013-06-25),

7. 8101571 - Treatment methods using NGF variants (2012-01-24),

8. 7935671 - Pantropic neurotrophic factors (2011-05-03),

9. 7528233 - Pantropic neurothrophic factors (2009-05-05),

10. 7452863 - NGF variants (2008-11-18),

11. 7144983 - Pantropic neurotrophic factors (2006-12-05),

12. 7067484 - AL-1 neurotrophic factor treatments (2006-06-27),

13. 6610296 - Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin (2003-08-26),

14. 6599717 - Invertebrate vascular endothelial growth factor receptor (2003-07-29),

15. 6511824 - Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use (2003-01-28),

Title: The Innovative Work of John William Winslow in Cancer Research

Introduction:

John William Winslow, a prolific inventor based in El Granada, CA, is renowned for his groundbreaking work in the field of cancer research. With an impressive portfolio of 24 patents, Winslow has significantly contributed to advancements in determining the likelihood of survival and predicting the likelihood of metastasis in cancer patients.

Latest Patents:

Winslow's recent patents focus on methods for accurately quantifying HER2 and/or p95 expression in individuals with HER2 positive cancer, providing crucial insights into the risk of brain relapse in these patients. These innovative methods offer a novel approach to assessing cancer progression and developing targeted treatment strategies.

Career Highlights:

Throughout his career, Winslow has made significant strides in the pharmaceutical and biotechnology sectors. He has held key positions at renowned companies such as Genentech, Inc. and Laboratory Corporation of America Holdings, where he has spearheaded research initiatives aimed at enhancing cancer diagnostics and personalized medicine.

Collaborations:

Winslow has collaborated with esteemed professionals in the industry, including Leonard G Presta and Roman Urfer. Together, they have combined their expertise to push the boundaries of cancer research and develop cutting-edge technologies for improving patient outcomes.

Conclusion:

John William Winslow's remarkable contributions to the field of cancer research underscore his commitment to innovation and improving healthcare outcomes for patients. His pioneering work in accurately predicting cancer progression and identifying treatment modalities marks him as a visionary in the field of biotechnology and pharmaceuticals.

Profile summary based on public USPTO records.